Skip to main content
Go to homepage

Perampanel in Children 1 month to 2 years

Safety and Efficacy of Perampanel in Children 1 month to 2 years

Description:

For complete study information, please view the study on clinicaltrials.gov

Interested in participating?
We are currently recruiting
Full IRB Study Title:
An Open-Label Study With an Extension Phase to Evaluate the Pharmacokinetics of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Subjects From 1 Month to Less Than 24 Months (<2 years) of Age With Epilepsy
IRB Study ID:
1057929
Lead Investigator
Michael Kohrman, MD

Director, Pediatric Neurology; Co-director, Tuberous Sclerosis Program; Pediatric Neurologist
Pediatric Epilepsy ProgramPediatric NeurologyTuberous Sclerosis ClinicNeuroDevelopmental Science CenterPediatric Sleep Center